149 related articles for article (PubMed ID: 31588566)
1. IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness.
Chen LY; Keddie S; Lunn MP; Bomsztyk J; Vitsaras E; Gupta R; D'Sa S
Br J Haematol; 2020 Feb; 188(4):511-515. PubMed ID: 31588566
[TBL] [Abstract][Full Text] [Related]
2. B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.
Schmidt K; Sack U; Graf R; Winkler W; Popp O; Mertins P; Sommermann T; Kocks C; Rajewsky K
Front Immunol; 2020; 11():602868. PubMed ID: 33343574
[TBL] [Abstract][Full Text] [Related]
3. IgM paraproteinaemic neuropathies.
Nobile-Orazio E
Curr Opin Neurol; 2004 Oct; 17(5):599-605. PubMed ID: 15367864
[TBL] [Abstract][Full Text] [Related]
4. Investigation and Management of Immunoglobulin M- and Waldenström-Associated Peripheral Neuropathies.
Tomkins O; Leblond V; Lunn MP; Viala K; Weil DR; D'Sa S
Hematol Oncol Clin North Am; 2023 Aug; 37(4):761-776. PubMed ID: 37385714
[TBL] [Abstract][Full Text] [Related]
5. Neuropathy and paraproteins: review of a complex association.
Rajabally YA
Eur J Neurol; 2011 Nov; 18(11):1291-8. PubMed ID: 21418441
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2012 May; (5):CD002827. PubMed ID: 22592686
[TBL] [Abstract][Full Text] [Related]
7. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
Le Cann M; Bouhour F; Viala K; Simon L; Tard C; Rossi C; Morel G; Lagrange E; Magy L; Créange A; Michaud M; Franques J; Echaniz-Laguna A; Antoine JC; Baron M; Arnulf B; Puma A; Delmont E; Maisonobe T; Leblond V; Roos-Weil D
Blood; 2020 Nov; 136(21):2428-2436. PubMed ID: 32959046
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups.
Ilyas AA; Quarles RH; Dalakas MC; Fishman PH; Brady RO
Ann Neurol; 1985 Dec; 18(6):655-9. PubMed ID: 2417543
[TBL] [Abstract][Full Text] [Related]
9. An update on monoclonal gammopathy and neuropathy.
Ramchandren S; Lewis RA
Curr Neurol Neurosci Rep; 2012 Feb; 12(1):102-10. PubMed ID: 22090258
[TBL] [Abstract][Full Text] [Related]
10. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
11. [Anti-myelin-associated glycoprotein antibody positive IgM monoclonal gammopathy related peripheral neuropathy: 11 cases and literature review].
Gao XM; Jia MN; Qian M; Ren HT; Zhang L; Shen KN; Cao XX; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):901-905. PubMed ID: 31856437
[No Abstract] [Full Text] [Related]
12. Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy.
Zivković SA
Expert Rev Neurother; 2006 Sep; 6(9):1267-74. PubMed ID: 17009914
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2006 Apr; (2):CD002827. PubMed ID: 16625561
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
15. IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy.
Campagnolo M; Zambello R; Nobile-Orazio E; Benedetti L; Marfia GA; Riva N; Castellani F; Bianco M; Salvalaggio A; Garnero M; Ruiz M; Mataluni G; Fazio R; Ermani M; Briani C
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1094-1097. PubMed ID: 28501820
[No Abstract] [Full Text] [Related]
16. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings.
Yeung KB; Thomas PK; King RH; Waddy H; Will RG; Hughes RA; Gregson NA; Leibowitz S
J Neurol; 1991 Oct; 238(7):383-91. PubMed ID: 1660064
[TBL] [Abstract][Full Text] [Related]
17. Characterization of neuropathies associated with elevated IgM serum levels.
Goldfarb AR; Sander HW; Brannagan TH; Magda P; Latov N
J Neurol Sci; 2005 Feb; 228(2):155-60. PubMed ID: 15694197
[TBL] [Abstract][Full Text] [Related]
18. Rituximab therapy in monoclonal IgM-related neuropathies.
Kilidireas C; Anagnostopoulos A; Karandreas N; Mouselimi L; Dimopoulos MA
Leuk Lymphoma; 2006 May; 47(5):859-64. PubMed ID: 16753870
[TBL] [Abstract][Full Text] [Related]
19. Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins.
Ilyas AA; Quarles RH; Dalakas MC; Brady RO
Proc Natl Acad Sci U S A; 1985 Oct; 82(19):6697-700. PubMed ID: 2413445
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; Lokhorst HL; van der Pol WL; Franssen H; Wokke JH; Notermans NC
J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1036-9. PubMed ID: 19684235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
